The contract refers to the concession in exchange of the Regional Market of Lechaio area of 102,381.67 sqm, to the Municipality of Corinth with the aim of creating a Biotechnology Park and the installation of biotechnology, innovation and high technology enterprises. The duration of the concession of use and exploitation of the property is determined in thirty (30) years from the signing of the contract with the possibility of extension for another ten (10) years.
The development of a Biotechnology and Innovation Technology Park by the Greek company of regenerative medicine Theracell Advanced Biotechnology and the American biotechnology company Orgenesis has been announced in the area. The total investment will amount to 80 million euros. The project was approved last November by the Interministerial Committee on Strategic Investments
Theracell Advanced Biotechnology was founded in 2013 and specializes in the development of innovative cell and gene therapy products and is involved in the distribution of a variety of Cell and Gene Therapy (CGT) products. The company's therapeutic portfolio extends to the fields of orthopedics, dermatology, nephrology, immuno-oncology and tissue repair and regeneration.
Through strategic partnerships, Theracell Advanced Biotechnology participates in the process of implementing Personalized Medicine tailored to the individual needs of the patient. One such case is the strategic cooperation with Orgenesis, with the aim of expanding the therapeutic processes.
The company will also provide cell therapies to patients, through this investment, something that the minister pointed out, among other things. It is noted that the required work for the implementation of the investment is scheduled to begin during 2022.
